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ABSTRACT 
 
This study aims to discover whether there is a correlation between atypical 
clinical presentations of Alzheimer’s disease (AD) and atypical distribution patterns of 
AD pathology. To provide a measure of the atypical clinical presentations, we obtained 
standardized neuropsychological test scores for a group of 345 subjects of the Boston 
University Alzheimer’s Disease Center cohort that had received a clinical or pathological 
diagnosis of AD. Each of the neuropsychological test scores included in our analyses was 
classified into one of five cognitive domains, according to the primary domain each test 
assesses: memory, executive function, attention, visuospatial function, and language. 
From these test scores, global cognitive performance scores and individual domain 
performance scores were calculated for a subset of 53 subjects that had brain tissue slides 
available for pathological analysis. Difference scores were computed for each domain, 
providing a within-subject comparison of performance between each individual cognitive 
domain and overall cognitive performance. For these same 53 subjects, tissue slides from 
six brain regions were obtained and digitally scanned. Neurofibrillary tangle (NFT) 
quantification was performed for all tissue slides using a computer algorithm modified to 
recognize AT8 staining patterns. NFT densities were then calculated for five general 
brain regions (frontal, parietal, temporal, limbic and occipital). In addition, a global NFT 
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density score was computed for each subject, averaging NFT densities across all regions. 
From these densities, difference scores were calculated for each brain region individually, 
providing a measure of how each region’s NFT density compares to the overall brain 
NFT density. Multiple linear regressions analyses were performed with five pairs of 
cognitive domain difference scores and region NFT density difference scores: memory 
difference scores and limbic difference scores, executive function difference scores and 
frontal difference scores, attention difference scores and parietal difference scores, 
visuospatial difference scores and occipital difference scores, and language difference 
scores and occipital difference scores. Though we expected to observe significant 
negative correlations between each of the five difference score pairs, the only statistically 
significant correlation observed was between memory difference scores and limbic 
difference scores (β= -0.361, p<0.05). These results suggest that poorer performance in 
memory-related neuropsychological tests, when compared to global cognitive 
performance, can predict higher NFT densities in limbic regions when compared to the 
overall brain pathology. Although no other difference score pairs showed any statistically 
significant correlations, many study limitations, including small sample size and 
simplifications in analysis, should be addressed in the future to provide better 
understanding of these atypical presentations of AD and their underlying pathologies. 
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INTRODUCTION 
Alzheimer’s disease (AD) is currently the most common form of dementia in the 
United States (Centers for Disease Control and Prevention [CDC], 2013). It is estimated 
that the number of people affected by the disease will reach 5.2 million in 2016, 
increasing to 13.8 million by 2050 (Hebert, Weuve, Scherr, & Evans, 2013) (See Figure 
1). Since one of the most important known risk factors for AD is advancing age, and the 
overall population of the US is aging, the rate of increase is not expected to plateau 
anytime soon (Lindsay et al., 2002; CDC, 2013). This growing, upward trend in AD 
cases has consequently garnered much attention over the years from concerned health 
professionals, research scientists and public health officials alike. What is most 
concerning is the fact that research advances have not kept up with the steep increase in 
AD cases. There are currently no effective treatments available to combat AD, which has 
undoubtedly exacerbated the crisis. Furthermore it is well known that developing 
treatments is a very time consuming, arduous and expensive process. However, as we 
further investigate the etiology of the disease and the many clinical manifestations it can 
have, we will be better equipped to correctly diagnose patients at earlier stages and 
explore new treatment targets, or at the very least establish preventative methods to 
attenuate what some might consider a devastating epidemic. 
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Figure 1: Projections for number of people affected by AD (in millions) from 2010 to 
2050  (Adapted from Hebert, Weuve, Sherr & Evans, 2013). 
 
Pathology of Alzheimer’s disease 
In order to attempt to comprehend how AD affects a patient, we must fist 
understand the physical changes that occur in the brain at a cellular level. The hallmarks 
of AD pathology include two main elements: extracellular deposits of a protein called 
amyloid-β peptide (Aβ), commonly referred to as senile plaques or Aβ plaques, and an 
accumulation of intracellular neurofibrillary changes within the tissue of the affected 
brain (Montine et al., 2012). The formation of Aβ plaques has been well characterized 
since the discovery of the disease in the early 1900s, and many hypotheses describing Aβ 
deposition as the driving force behind the pathogenesis of AD have been formulated. 
Hardy and Higgins (1992), for example, developed the Amyloid Cascade Hypothesis 
which has been well accepted among the scientific community. Their hypothesis states 
	 3	
that Aβ deposition is the primary cause for the deterioration of brain tissue because it 
induces the pathological neurofibrillary changes that ultimately result in neuronal cell 
loss. This and other Aβ plaque-centered hypotheses consequently led to a surge in 
research efforts viewing Aβ plaques as treatment targets. But, early trials for drugs that 
eliminate these plaques have failed, shifting the research focus to understanding the 
second pathological component of AD: the neurofibrillary changes (Bakota & Brandt, 
2016). 
These pathological neurofibrillary changes involve a protein called microtubule-
associated protein Tau, or tau for short, which is involved in many aspects of normal cell 
processes, but is most importantly implicated in stabilizing the axonal microtubules of 
neurons (Khan & Bloom, 2016). It was discovered that tau becomes hyperphosphorylated 
in patients with AD, which causes it to lose its functional capacity and become tangled, 
forming paired helical filaments that aggregate to become neurofibrillary tangles (NFTs) 
(Serrano-Pozo, Frosch, Masliah, & Hyman, 2011). This hyperphosphorylation therefore 
causes the breakdown of the microtubule network of neurons, resulting in loss of 
dendrites and axons, and ultimately leading to cell death (Alonso et al., 2010) (See Figure 
2). As NFTs accumulate throughout the brain over time and cells continue to die, the 
neuronal loss becomes so great that the tissues affected become atrophic, compromising 
cognitive functions (Lorenzi et al., 2016). 
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Figure 2: Microtubule Associated Protein Tau (p-tau) and hyperphosphorylated tau 
(Adapted from Tatarnikova, Orlov, & Bobkova, 2015). 
 
Although these pathological characteristics of AD are very well known, the 
precise etiology and chronology of the pathogenesis is still a matter of controversy 
among the scientific community. While some scientists strongly believe research focus 
should lie in understanding the specific interactions between Aβ plaques and NFTs 
(Tatarnikova, Orlov, & Bobkova, 2015), recent research has demonstrated that NFTs 
correlate better with cognitive decline than Aβ plaques do (Nelson et al., 2012). In fact, 
there have been cases where significant Aβ deposition and no evidence of tau pathology 
has been observed in asymptomatic, cognitively intact patients (Sperling et al., 2009). 
The occurrence of these cases strengthens the support for viewing NFTs as possible 
treatment targets and should incentivize research to understand precisely how NFTs 
affect the brain. 
It is inaccurate to think that NFTs have been entirely overlooked up until recently, 
however. In fact, NFT formation has been very well characterized along with Aβ 
deposits. In 1991, for example, scientists discovered a pattern in how NFTs tended to 
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accumulate across brain regions. Researchers described this distribution pattern and 
developed a systemic way of using it to classify AD progression into six different stages. 
The stages are determined according to the regions in the brain where there is evidence of 
NFT formation and the density of NFTs in each region. The early stages of the disease, 
Stages I and II (the transentorhinal stages), are marked by formation of NFTs in the 
transentorhinal cortex. The following stages, Stages III and IV (the limbic stages), 
involve NFT formation in the limbic system, after which isocortical involvement is 
observed in Stages V and VI (the isocortical stages) (Braak & Braak, 1991) (See Figure 
3). Pathologists presently use these Braak stages, named after the scientists that described 
them, to characterize the extent of pathological changes observed in an autopsied brain, 
and therefore provide a measure of how far AD had progressed before the patient 
deceased.  
 
Figure 3: Braak staging pattern of neurofibrillary degeneration. Shading indicates 
the concentration of NFTs, with darker shading indicative of higher NFT density. 
Amyg = Amygdala; EC = Entorhinal cortex; CA1 = Cornus ammonis 1 
hippocampal subfield; Cg = Cingulate cortex; Prec = Precuneus; 4 = Primary motor 
cortex; 3-1-2 = Primary sensory cortex; 17 = Primary visual cortex; 18 = Associative 
visual cortex. (Adapted from Serrano-Pozo, Frosch, Masliah, & Hyman, 2011). 
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To determine the Braak stage, pathologist may use a variety of staining methods 
that facilitate detection of NFTs in brain tissue. Most commonly, an 
immunocytochemical staining technique known as AT8 staining is employed, which uses 
an AT8 antibody that selectively binds to phosphorylated tau (p-tau) (Braak, Alafuzoff, 
Arzberger, Kretzschmar, & Del Tredici, 2006). This technique stains the cells affected by 
NFTs a dark brown color and they typically appear with a characteristic triangular shape 
(See Figure 4). Only after autopsy, when the staining techniques and assessments of brain 
tissues have been completed, can the pathologists definitively diagnose AD 
retrospectively. However, it is in a clinical setting where we face the toughest challenges 
in diagnosis. Currently, physicians’ ability to accurately diagnose AD during a patient’s 
life is very limited. 
 
 
Figure 4: Example of typical NFT structures (some circled) in gray matter viewed at 
20x magnification with the use of AT8 staining method. 
 
Clinical Diagnosis of Alzheimer’s disease 
AD progression should be viewed as a spectrum; a patient with the disease 
initially has no cognitive deficits but overtime shows worsening signs of cognitive 
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impairment leading to a dementia state. This spectrum can been divided into three stages: 
the asymptomatic stage, the symptomatic predementia stage, and the dementia stage 
(Jack et al., 2011). One of the most significant challenges in the clinical diagnosis of AD 
has been the inability to detect the disease at the earliest asymptomatic stage, also known 
as the prodromal or preclinical stage of AD, when intervention could be most effective.  
It has been observed that AD-related pathological changes can begin to 
accumulate up to 20 years before any clinical symptoms become apparent (Villemagne et 
al., 2013). Even though some cognitive deficits might occur at this time, they are 
extremely difficult to detect and might go unnoticed unless formally assessed (Amieva et 
al., 2008). This inability to detect early pathological changes has caused a lot of drug 
trials and experimental treatments to fail, because, by the time symptoms are noticed and 
treatment is started, it is believed that the amount of pathological damage incurred by the 
brain tissue is insurmountable, which renders treatments futile (Bakota & Brandt, 2016). 
However, further investigating the precise etiology of AD will allow us to develop more 
effective diagnostic procedures that could detect this inconspicuous pathology occurring 
at the onset of the disease. Indeed, there have already been great efforts to tackle this 
problem head-on.  
In 2007 the International Working Group for New Research Criteria for the 
Diagnosis of Alzheimer’s Disease developed updated criteria for the diagnosis of AD to 
reflect recent findings, including the introduction of biomarkers in diagnostic testing. 
These biomarkers include total tau, p-tau, and Aß protein levels that are measured in the 
cerebrospinal fluid of a patient via lumbar puncture. Along with imaging techniques like 
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structural magnetic resonance imagine and molecular neuroimaging with positron 
emission tomography, these biomarkers provide a measure of the possible underlying 
pathological changes occurring in a patient’s brain, and could ultimately be used to 
diagnose AD at an earlier stage. An earlier diagnosis would allow for early intervention 
with treatment currently available to delay disease progression (Dubois et al., 2014). 
These biomarkers have only been approved for use in diagnoses in a research setting, 
since further research needs to be performed before they can be effectively implemented 
in a clinical setting, but they certainly give hope that we will soon be able to detect the 
disease earlier, hopefully improving disease outcomes. Furthermore, the use of these 
biomarkers could be used as a tool for differential diagnosis, allowing clinicians to 
determine if a patient’s dementia could be due to underlying AD-related pathology, or 
some other type of pathology (Blennow & Zetterberg, 2015). 
Once a patient reaches the pre-dementia stage, there may be expressed concern 
regarding a change in their cognition, either directly from the patient or a close relative. 
Typically a patient will have impairment in one or more cognitive domains, with episodic 
memory being the cognitive domain most commonly affected in AD (Weintraub, 
Wicklund, & Salmon, 2012). However, an important distinction is that at this early stage 
the cognitive impairments are not significant enough to affect the patient’s independence 
or ability in performing daily functions. These patients will typically be diagnosed with 
Mild Cognitive Impairment (MCI) upon formal neuropsychological testing (Albert et al., 
2011; Janoutová, Šerý, Hosák, & Janout, 2015).  
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As the disease progresses, the patient will typically demonstrate a progressive 
significant decline in cognitive abilities, worsening at an increasing rate over time, and 
eventually develop deficits that are sufficient to interfere with their daily functions and 
activities (Teri, McCurry, Edland, Kukull, & Larson, 1995). It is at this point when a 
physician will most likely diagnose the patient with possible or probable AD dementia. 
As mentioned before, a definite diagnosis of AD dementia cannot be achieved until the 
brain tissue is assessed at autopsy, therefore a physician’s ability to arrive at this 
diagnosis relies heavily on objective cognitive assessments, like neuropsychological 
testing, and other information gathered from a patient’s history (McKhann et al., 2011).  
Neuropsychological tests are a tool used to gauge a patient’s cognitive abilities 
across multiple domains, and can be observed longitudinally to detect any decline in 
performance across time (Weintraub et al., 2012). One of the more useful 
neuropsychological evaluation tools available, for example, is the Clinical Dementia 
Rating (CDR) scale, which was developed to detect any signs of AD-related dementia in 
a patient and provide a measure of the extent to which cognitive abilities have been 
compromised. The scale evaluates six different domains including memory, orientation, 
problem solving, and personal care (Morris, 1997). Like the CDR scale, there are a 
variety of neuropsychological tests that can be used in a clinical setting to help determine 
a patient’s cognitive deficits. Some tests can assess performance across multiple 
cognitive domains, whereas others can be used to look at specific domain deficiencies.  
Traditionally AD has been thought of as a disease that primarily affects episodic 
memory. In fact, most patients that suffer from AD typically present with memory 
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problems initially, after which, as the disease progresses and multiple regions of the brain 
are affected by pathological changes, there is significant decline in other cognitive 
functions unrelated to memory (non-amnestic). However, there have been subsets of 
cases of patients with AD that demonstrate a different set of symptoms initially and 
present with a different clinical course for the disease than is usually observed 
(Ossenkoppele et al., 2015). The symptomology presentations that stray from what is 
usually observed in the majority of patients with AD have been categorized under the 
name “atypical” AD. These varying clinical presentations have made some researchers 
realize there is not a one-size-fits-all approach when diagnosing AD.  
 
Atypical Alzheimer’s disease 
These atypical presentations of AD have garnered much attention in recent years. 
This has been due to the discovery of subsets of AD cases where patients’ brains display 
anatomical patterns of pathology different from that observed in the majority of AD 
cases, which fall within the predictable Braak staging patterns previously mentioned 
(Galton, Patterson, Xuereb, & Hodges, 2000). These might be more common than 
previously thought, as it has been estimated that about 25% of patients don’t display the 
typical pattern of pathology seen with AD (Whitwell et al., 2012). One example of these 
differing patterns was observed in a subject that had relative sparing of the hippocampus, 
whereas other cortical areas were heavily affected by AD pathology (Giannakopoulos, 
Hof, & Bouras, 1994). Additionally, it has been observed that these different patterns in 
pathology distribution may not be entirely at random or isolated cases, as some 
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researchers have found that, for example, an atypical presentation of AD where executive 
function is more strongly affected than memory, is in fact highly hereditable (Mez et al., 
2016). 
Based on the relative density of NFTs in the hippocampus and different 
association cortices, these pathological variants of AD can been classified into three 
different subtypes: hippocampal sparing (HpSp AD), limbic predominant (LP AD), and 
typical AD. In HsSp AD there is a higher concentration of NFTs in cortical areas with 
relative sparing of the hippocampus, LP AD shows disproportionately higher 
concentration of NFTs in the hippocampus and other limbic structures with very sparse 
NFTs found in cortical areas, and typical AD follows the Braak scheme of pathology 
(Janocko et al., 2012). It has been hypothesized that these cases of atypical pathological 
distribution of AD hallmarks accounts for the 10% of patients that initially present with 
symptoms other than episodic memory loss (Murray et al., 2011). Therefore it is 
important to determine what specific clinical symptoms could these patients present with. 
Understandably, it’s significantly more difficult to characterize clinical 
presentations of atypical AD, since there may be overlap with other syndromes or 
diseases (Janocko et al., 2012). Furthermore, with no techniques of definitively 
diagnosing AD in vivo it becomes increasingly difficult to know if the underlying cause 
of some form of non-amnestic cognitive deficit is due to AD-related pathology. However, 
there is some understanding of some focal cortical syndromes that are caused by AD 
pathology. These include problems with visuospatial abilities, more commonly referred 
to as posterior cortical atrophy, fluent and non-fluent aphasia, and executive function, 
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also known as dysexecutive syndrome, among others. An example of the atypical 
symptom profile a patient with dysexecutive syndrome may present with includes deficits 
in “planning, judgment, reasoning, problem solving, organization, attention, abstraction 
and mental flexibility” (Stuss & Alexander, 2007). 
 Unfortunately, as Murray et al. (2012) explain, “the frequency and clinical 
implications of atypical AD have been neglected in research on large autopsies series.” 
This is very concerning, as one can see how a patient that could be suffering from an 
atypical form AD could be diagnosed as having a different type of dementia, as the 
clinical profile does not match that of typical AD. Ossenkoppele et al. (2015) observed 
how 52% of patients that presented with an atypical behavioral variant of AD actually 
met the criteria for possible behavioral-variant frontotemporal dementia, and this only 
refers to one of many variations or subtypes of atypical AD. This could indicate that there 
is probably a high likelihood of misdiagnosis of patients suffering from atypical AD.  
As mentioned previously, a timely and accurate diagnosis of AD is of crucial 
importance. Being able to use biomarkers and effectively recognize early signs of the 
disease could allow for early intervention and therefore treatments to be effective, 
changing the course of a patient’s cognitive decline. This applies for both typical and 
atypical AD. Unfortunately, however, our understanding of the specific atypical 
presentations and their underlying neuropathology is very limited.  
Drawing parallels between the regions affected by AD pathology and the 
consequent cognitive symptoms observed in a patient may seem very straightforward. 
Considering how neuroscience research has advanced in past years and how scientists 
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have been able to assign specific cognitive functions to brain structures and regions, it 
may seem intuitive and redundant to perform a study that correlates cognitive deficits 
with the distribution of AD pathology. However, there has been little to no studies 
performed where specific parallels have been drawn between these atypical clinical 
presentations and atypical pathology distributions of AD, which justifies this 
clinicopathological study of atypical AD. 
The main objective of this thesis was to analyze correlations that may exist 
between atypical clinical presentations of AD and the neuroanatomical distribution of 
AD-related pathology observed. For this we retrospectively analyzed the outcomes in 
neuropsychological testing performed on patients that were clinically or pathologically 
diagnosed with AD. The neuropsychological tests were divided into five cognitive 
domains to identify the specific cognitive deficits the patients presented with during life. 
To analyze neuroanatomical distribution of NFTs, tissues from five different brain 
regions were obtained for a subset of the patients previously mentioned. The tissues were 
digitally scanned and NFT quantification was performed using computer software (See 
Methods).  
We predict that a higher NFT density in the frontal region of the brain, compared 
to the overall pathology of the brain, correlates strongly with poorer performance in 
executive function testing when compared to performance in other cognitive domains. 
Similarly, we predict higher NFT density in the limbic region strongly correlates with 
poorer performance in memory tests, higher NFT density in the parietal region strongly 
correlates with poorer performance in attention tests, higher NFT density in the occipital 
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region correlates strongly with poorer performance in visuospatial function tests, and 
higher NFT density in the temporal region will correlate with poorer performance in 
language tests.  
By drawing correlations between the anatomical distribution of AD pathology in 
the brain and the specific cognitive deficits that a patient may present with, we hope to 
draw attention to the spectrum of symptoms that may be caused by underlying atypical 
AD pathology. By understanding these varying types of atypical AD and their 
correlations with clinical profiles, we hope to incentivize additional research that could 
eventually benefit patients that suffer from these atypical forms of AD and decrease their 
rate of misdiagnosis. Additional studies into the subtypes of atypical AD will also allow 
for clinicians to recognize these clinical presentations sooner and associate them with 
possible underlying AD pathology, which will consequently allow for the correct 
available treatments to be started at an earlier stage of the disease. This would be crucial 
in the disease outcome for patients, since, as mentioned previously, early intervention is 
extremely important in changing the course of the disease—at least until more effective 
treatments are developed.  
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METHODS 
Study sample 
 All of the subject data for this study were obtained from the Boston University 
Alzheimer’s Disease Center (BU ADC). The BU ADC is 1 of 29 centers funded by the 
National Institutes of Health to research AD, improve clinical care, and educate others 
about the disease. The center, established in 1996, collects donated brains from patients 
with dementia, patients with AD and controls (patients without AD). A cohort of about 
400 subjects that are enrolled in studies at the BU ADC are followed and evaluated 
annually at the center, where they are administered a battery of neuropsychological tests 
the outcomes of which are recorded and analyzed throughout the patient’s lifetime.  All 
demographic data is obtained at the patient’s initial visit by self-report. The outcomes of 
the neuropsychological tests along with the patient’s history are used to clinically 
diagnose subjects at a consensus meeting at the BU ADC, in which a panel of trained 
neurologists, neuropsychologists and other clinicians review the patients’ profiles and 
collectively arrive at a consensus diagnosis. Once the patient has deceased and their brain 
is donated to the center, pathologists analyze the tissue, blinded to the patient’s clinical 
profile, and a pathological diagnosis is determined. Pathological and clinical diagnoses 
are determined according to criteria established by the National Institute on Aging. The 
pathological findings and other data are included in the patients’ files, which can later be 
used retrospectively for other studies. The data for all subjects is recorded and maintained 
by the BU ADC Data Core group. 
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To obtain data related to the anatomical distribution of NFTs we defined a study 
cohort that will be referred to as the pathological sample. For this sample we included 
patients that were brain donors and received a clinical consensus diagnosis of possible or 
probable AD or pathological diagnosis of AD, regardless of comorbid pathologies. All 
patients selected were required to have undergone neuropsychological testing in life, and 
they must have received a CDR score of 0.5 or 1 in at least one of the neuropsychological 
testing sessions, which is indicative of mild AD-related dementia (Morris, 1997). These 
patients were also required to have had an autopsy completed and have brain tissue slides 
available for NFT quantification. A data request was submitted to the BU ADC Data 
Core group to obtain case numbers of patients who met all criteria. A total of 64 patients 
met the pathological sample criteria (See Table 1 for demographic information). 
To analyze performance in neuropsychological testing of the pathological sample 
we decided to broaden the inclusion criteria and create a second study cohort, which will 
be referred to as the neuropsychological sample. The subjects included in this sample 
were all patients who received a clinical diagnosis of possible or probable AD or a 
pathological diagnosis of AD (confirmed via autopsy). These subjects were required to 
have had neuropsychological testing performed in at least one visit, but it was not 
necessary for them to have had an autopsy performed (and, therefore, a pathological 
diagnosis was not required). By including a larger number of patients via widening the 
inclusion criteria we were able to more accurately gauge patients’ performance across the 
many neuropsychological tests (see Statistical Analyses section). A total of 345 patients 
met these criteria and were included in the neuropsychological sample (the 64 subjects 
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from the pathological sample were included in the neuropsychological sample of 345) 
(See Figure 5). 
 
Figure 5: Flow chart of neuropsychological and pathological sample selection. 
BU	ADC	cohort	
Clinical	dx	of	possible/probable	AD	OR	pathological	dx	of	AD	
Neuropsychological	testing	performed	at	least	once	
NEUROPSYCHOLOGICAL	SAMPLE	(N=345)	
CDR	SCORE	of	0.5	or	1	in	at	least	one	testing	session	
Brain	donors	(pathological	data	and	brain	tissue	slides	available)	
PATHOLOGICAL	SAMPLE	(N=64)	
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All subject data received from the BU ADC Data Core group was anonymous, 
with each subject having a unique identification number that had been previously 
assigned. 
 
Procedures 
 Our methods and procedures were based off a study by Murray et al. (2011) that 
aimed to compare clinical, demographic, pathological and genetic characteristics of 
subjects classified into the three different atypical AD subtypes previously mentioned: 
HpSp AD, LP AD, and typical AD. For our study, brain tissue slides that had been 
previously stained by pathologists at the BU ADC with the AT8 staining technique were 
obtained for subjects of the pathological sample. The six slides obtained for each subject 
were from six different tissue blocks (i.e. brain regions): inferior parietal lobe (block 4), 
middle frontal gyrus (block 7), superior temporal lobe (block 10), amygdala and 
entorhinal cortex (block 11), hippocampus at the level of the lateral geniculate nucleus 
(block 14), and the occipital lobe (block 25). These specific tissue blocks were chosen in 
similarity with the study by Murray et al. (2011), but we included the amygdala and 
occipital lobe for a more complete picture of the association cortices affected by AD 
pathology. 
The stained slides were scanned at 20x magnification using a ScanScope XT 
(Aperio, Vista, CA, USA). The scans yielded one image per slide, showing the entire 
tissue contained within each slide. The scanner was used in conjunction with ImageScope 
software (version 12.2.1.5005) that allows for the storage and analysis of digital images 
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of tissue slides of any type. Using the ImageScope software, annotation layers were 
created in every scanned image to delineate areas of interests for analysis. For slides of 
blocks 4, 7, 10 and 25, annotation layers were drawn to delineate all of the gray matter, 
including all layers of cortical neurons, that was contained within the slide. For slides of 
block 14, separate annotation layers were created for the different subfields of the 
hippocampus, namely cornus ammonis (CA) 1, CA 2/3, CA 4 and subiculum. The 
hippocampal regions CA 2 and CA 3 were included in the same annotation layer due to 
the increased difficulty in accurately discerning limits between both regions. For slides of 
block 11, the annotation layer delineated solely the amygdala. 
All annotation layers were created with the consultation of a BU ADC pathologist 
to ensure the appropriate regions were being selected by use of neuroanatomical 
landmarks and structural features. Any artifacts due to staining and/or scanning were 
excluded from annotation layers by use of the negative pen tool in ImageScope, which is 
used for indicating areas within an annotation layer that are to be ignored when analyzing 
the image. The techniques used to delineate annotation layers were consistent throughout 
all cases and all slides, and all procedures involving slides were done blinded to subjects’ 
clinical profile. 
To perform NFT quantification, the Nuclear macro template algorithm of 
ImageScope (version 12.2.1.5005) was modified to identify cells with heavy AT8 
staining, which is indicative of a high concentration of p-tau, and that had the typical 
morphology of a cell affected by an NFT. The cells on the tissue that fell within the range 
of the color intensity (staining intensity) and shape that were specified in the algorithm 
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were considered to be a “positive” cell, whereas cells that didn’t meet the threshold were 
considered “negative” cells. Positive cells in this context therefore indicate an NFT 
structure; negative cells are “normal” cells void of any staining and therefore unaffected 
by NFTs (see Appendix 1).  
To achieve the final parameters indicated above we used the software’s test 
algorithm feature that allows for the manual input of algorithm parameters while viewing 
a preview of the algorithm analysis. This test was performed with different ranges of 
parameters until the desired effect was observed. The algorithm was tested across 
multiple areas of randomly selected tissue slide images. Once the algorithm was 
established, it was run on the annotated digital slide images obtained for all subjects. 
The ImageScope software automatically ran the analysis across all images and 
counted the number of positive and negative cells within the annotation layers created for 
each image. The software generated many data points of which we only used the positive 
cell count, which is the number of NFTs in the tissue image analyzed, and the total area 
that was analyzed by the software (the area of the annotation layers drawn). The 
ImageScope software allows for the data to be exported into a .CSV file, which was later 
imported onto SPSS to perform statistical analyses. 
A total of 384 tissue slides (6 slides per subject, for 64 subjects) were scanned and 
analyzed using these methods.  
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Neuropsychological data 
The neuropsychological data received from the BU ADC Data Core group 
included the battery of neuropsychology tests that are administered on a yearly basis to 
all patients that participate in studies done by the BU ADC. After looking at all of the 
available data, we selected a total of 58 neuropsychological tests of interests from the 
available set of tests based on the cognitive domains we were interested in analyzing. The 
cognitive domains of interest included: memory, executive function, attention, 
visuospatial function and language. After consulting with a neurologist and some 
clinicians involved with administering the tests, we classified each of the 58 tests into the 
primary cognitive domain they assess. Although the majority of these tests can be used to 
assess a variety of cognitive functions, to simplify our analysis we considered only the 
domain that we found was most strongly assessed by each test. The table below identifies 
all of the 58 tests that were included in our data and the primary domain classification we 
assigned to each test. The total breakdown of tests was as follows: 28 tests for memory, 
10 tests for executive function, 10 tests for attention, 6 tests for visuospatial function and 
4 tests for language. The data was received from the BU ADC Data Core group as an 
SPSS file, which was imported onto SPSS where further statistical analyses were 
performed. 
Since the majority of subjects had neuropsychology test data from multiple visits 
to the BU ADC over time, we determined to only use test scores from a specified visit of 
interest. The visit of interest was determined to be the first visit at which the subject 
received a clinical consensus diagnosis of possible or probable AD. Out of the 345 
subjects of the neuropsychological sample, 338 received a diagnosis of possible or 
	22	
probable AD. There were 7 subjects that did not receive a consensus diagnosis of 
probable or possible AD at any point, but received a neuropathological diagnosis of AD 
after autopsy. For these 7 subjects, the visit of interest chosen was the first visit at which 
they received a CDR score greater than or equal to 0.5 or the first visit at which they 
received a diagnosis of probable MCI or possible MCI, which is indicative of cognitive 
impairment. Using filters in the SPSS software, we were able to select the visit of interest 
for each subject and only include the neuropsychological test scores from that specific 
visit in our analyses. 
 
Statistical Analyses 
 The statistical analyses performed with the study data were done using IBM SPSS 
Statistics software (version 20).  
 
Neurofibrillary tangle data 
 The data obtained for NFTs included the number of NFTs counted by the 
software for each tissue slide and the total area analyzed (the annotation layer area where 
NFTs were counted). Because of the varying tissue sizes and anatomical differences 
between subject tissues, and therefore their annotation layers, we calculated a total NFT 
density for each brain region of each patient. To do this we divided the total NFT count 
by the analysis area (annotation layer area) for each tissue slide, both data points which 
the ImageScope software provided. Once this was completed, we had the NFT density 
(NFTs/mm2) for every region of each of the 64 pathological sample subjects.  
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 Once the NFT densities were computed, Z-scores were calculated for NFT 
densities in each brain region across all subjects. Calculating a Z-score allowed us to 
standardize the densities for each region across all subjects, which allowed us to compare 
each patient’s region densities to the average density of the entire pathological sample 
cohort. This is done because calculating the Z-score sets the average NFT density of a 
particular region to 0, and the standard deviation to 1. The values obtained for each 
subject therefore indicates how far a subject’s particular NFT density is from the sample 
mean for the same region. Furthermore, calculating the Z-score will allow us to compare 
NFT density data with the neuropsychological data, which uses very different scales with 
different units. To simplify analyses, we averaged the Z-scores across all of the 
hippocampal subsections (CA 1, CA 2/3, CA 4, and subiculum) as well as the amygdala, 
so that we had an average Z-score for a combined limbic region. Afterwards we had five 
region Z-scores for every subject: inferior parietal, medial frontal, superior temporal, 
limbic, and occipital.  
 With the Z-scores we obtained, we calculated a global NFT Z-score for each 
subject by averaging the Z-scores across all of their five regions. This global NFT Z-
score gives us an overall view of how each subject’s overall pathology compares to the 
rest of the sample. In order to observe which regions were more strongly affected by 
NFTs for a particular subject, we subtracted the global NFT Z-score from each of the 
region Z-scores, giving us a difference score for each region of every subject. The greater 
the absolute value of a difference score is, the larger the difference in NFT density 
between that particular region and the overall global pathology. If the difference score is 
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negative, that specific region was found to have a lower NFT density than the rest of the 
brain, and vice versa.  
These difference scores were then classified into one of five general regions 
according to the brain region they represented: frontal, parietal, limbic, occipital and 
temporal. The difference score calculated from the middle frontal gyrus (block 7) was 
classified as the “frontal difference score,” the difference score from the inferior parietal 
lobe (block 4) was classified as the “parietal difference score,” the difference score for 
the limbic region (blocks 14 and 11) was the “limbic difference score,” the superior 
temporal lobe difference score was the “temporal difference score,” and the occipital lobe 
difference score was classified as the “occipital difference score.” 
 
Neuropsychological tests 
For each of the 58 neuropsychological tests we looked at for the study sample, we 
calculated the percent of missing data points (percent of subjects that did not receive a 
score for a particular test at the visit of interest) across all subjects. To try and attenuate 
the effect of missing data on analyses, we excluded neuropsychological tests that had a 
percentage of missing data greater than or equal to 70%. A total of 19 neuropsychological 
tests did not meet this missing data criterium and were therefore excluded from analysis. 
The consequent number of neuropsychological tests per domain was updated as follows: 
15 tests for memory, 8 for executive function, 9 for attention, 3 for visuospatial function, 
and 4 for language. 
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Since every neuropsychological test is scored differently, we decided to also 
calculate Z-scores in order to compare performance across all subjects. The Z-score, as 
with the NFT density data, allows us to determine how many standard deviations the 
score of a particular subject is compared to the mean of the entire subject sample, 
therefore a Z-score was calculated for each of the tests for every subject. Afterwards we 
calculated the average Z-score for each subject across all tests for a specific domain. For 
example, each subject received a “memory Z-score” which was calculated by averaging 
all Z-scores of the neuropsychological tests that were classified under the memory 
category (See Table 2). This average would therefore indicate an overall performance 
across all memory tests. The same was done for the other four cognitive domains. These 
average scores would therefore allow us to compare performance across tests of different 
domains to better understand which domains were most affected in each individual 
subject. 
Once these five domain scores were obtained for all patients, a global Z-score was 
calculated by averaging the scores across all domains for each patient. This would give us 
a measure of the overall global performance of a subject in neuropsychological testing, 
weighing each domain equally.  
As with the NFT density data, the global average Z-score was subtracted from 
each individual domain score for each subject. All subjects therefore received a 
difference score for each domain, which allows us to compare individual domain 
performance with the subject’s global performance. In this case a negative difference 
	26	
score would indicate poorer performance in a particular domain compared to their overall 
global performance, and vice versa. 
Of the 64 neuropathological sample subjects, a total of 11 subjects had missing 
domain Z-scores due to missing neuropsychological testing data, therefore they were 
excluded from analysis. A total of 53 subjects therefore received the five difference 
scores that were utilized for regression analysis. 
 
Linear Regression Analyses 
 As mentioned above, a total of 53 subjects from the pathological sample received 
five difference scores for each cognitive domain (memory, executive function, attention, 
visuospatial function, and language), and five difference scores for each brain region 
(frontal, parietal, temporal, limbic, and occipital). To observe correlations between each 
subject’s performance in neuropsychological testing and the NFT densities of each brain 
region, we performed regression analyses using the difference scores obtained. 
 Linear regression analyses were performed with the data. The analyses looked at 
correlations between the memory difference scores and limbic difference scores, 
executive function difference scores and frontal difference scores, attention difference 
scores and parietal differences scores, visuospatial difference scores and occipital 
difference scores, and language difference scores and occipital difference scores. The 
independent variable (predictor) was always the domain difference score, whereas the 
dependent variable was always the region NFT density difference score. This is because 
we wanted to see how well of a predictor performance in neuropsychological testing is 
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for NFT density in particular domain-region pairs. For all regression analyses we 
controlled for age of death, sex, race and years of education, by including these data 
points as covariates. 
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RESULTS 
Basic demographic frequencies were calculated for the pathological sample, and 
the demographic distribution is displayed in Table 1 below. 
 
Table 1: Basic demographic information for pathological sample cohort (N=64). 
Pathological Sample Size: N=64 
Sex 
Women 24 (37.5%) 
Men 40 (62.5%) 
Race 
African American 3 (4.7%) 
White 61 (95.3%) 
Ethnicity 
Hispanic 0 
Non-Hispanic 64 (100%) 
Education 
Years 15.26 (2.92) 
Age at Death 
Years 85.72 (8.34) 
APOEε4 
Carrier 19 (29.7%) 
Non-carrier 0 
Missing 45 (70.3%) 
 
 The neuropsychological tests were evaluated and classified into the domain 
categories displayed in Table 2 below. Tests that did not meet the 70% missing data 
cutoff (marked with “*”) were not included in the study analyses. 
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Table 2: The battery of neuropsychological tests of interests administered to 
subjects and the primary domain they assess clinically (M=Memory, EF=Executive 
Function, A=Attention, V=Visuospatial function, and L=Language). Tests marked 
with (*) were excluded from analysis (See Statistical Analysis section). 
Test Primary 
Domain 
Test Primary 
Domain 
Animals L Trails A Time A 
Vegetables L Trails A Correct Lines A 
Boston Naming Test L Trails B Time EF 
NAB Bill Payment* EF Trails B Correct Lines EF 
Cerad Trial 1 M NAB Driving Scenes* A 
Cerad Trial 2 M Digit Symbol A 
Cerad Trial 3 M NAB Design Construction* V 
Cerad Delay M NAB Visual Discrimination* V 
Cerad Recognition (Yes) M Hooper V 
Cerad Recognition (No) M NAB Judgment* EF 
Logical Memory Immediate M FAS L 
Logical Memory Delay M DRST Span* M 
Visual Reproduction Immediate M WAIS-III Similarities EF 
Visual Reproduction Copy* V Clock Drawing Test Copy V 
Visual Reproduction Discrimination* M Clock Drawing Test Command EF 
Visual Reproduction Delay M Dementia Rating Scale A 
Visual Reproduction Recognition M Dementia Rating Scale Ini/Psv EF 
NAB List Learning Trial 1+2+3 M Dementia Raiting Scale Construction V 
NAB List Learning Short Delay M Dementia Rating Scale Concept EF 
NAB List Learning Long Delay M Dementia Rating Scale Memory M 
NAB Daily Living Memory Immediate* M VADS A 
NAB Daily Living Memory Delay* M Verbal Paired Associates: First Recall Easy* M 
NAB Daily Living Memory 
Recognition* M Verbal Paired Associates: First Recall Hard* M 
Grooved Pegboard Dominant A Verbal Paired Associates: Second Recall Easy* M 
Grooved Pegboard Non-dominant A Verbal Paired Associates: Second Recall Hard* M 
Digit Span Forward Trials A Verbal Paired Assocaites: Third Recall Easy* M 
Digit Span Forward A Verbal Paired Associates: Third Recall Hard* M 
Digit Span Backwards Trials EF Verbal Paired Associates: Delayed Recall Easy* M 
Digit Span Backwards EF Verbal Paired Associates: Delayed Recall Hard* M 
 
When performing a multiple linear regression analysis with the memory 
difference scores, sex, race, age of death and years of education as the independent 
variables and the limbic difference scores as the dependent variable, an overall R-squared 
value of 0.241 was obtained with a p-value of 0.02, which is indicates statistical 
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significance for the linear regression as a whole. When looking at each covariate 
individually, however, we find that only memory difference scores had a statistically 
significant correlation with limbic difference scores, with a standardized β1 value of -
0.361 (p=0.009). All other correlations were not statistically significant, with p-values 
much higher than 0.05.  
 The multiple linear regression analysis performed with executive function 
difference scores and control variables as the independent variable and the frontal 
difference scores as the dependent variable yielded an R-squared value of 0.067 and a p-
value of 0.659, which indicates the linear model did not show a statistically significant 
correlation. When looking at the variables individually, no correlations were found to be 
statistically significant (p>0.05), and the standardized β1 value for executive function 
difference scores was 0.018 (p=909). 
For attention difference scores as the independent variable and the parietal 
difference scores as the dependent variable (controlling for the previously mentioned 
covariates), we observed an R-squared value of 0.046 and p-value of 0.809. Once again, 
this multiple linear model was not statistically significant. Looking at the covariates 
individually, none were significantly correlated, with attention difference scores having a 
standardized β1 value of -0.126 (p=0.416). 
The multiple linear regression for visuospatial difference scores as the 
independent variable and the occipital difference scores as the dependent variable 
(controlling for demographic variables) yielded an R-squared value of 0.070 and a p-
value of 0.622. Neither the regression model, nor the individual correlations between 
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each covariate and the dependent variable were statistically significant, with visuospatial 
difference scores yielding a standardized β1 value of 0.067 (p=0.640). 
 Finally, a multiple linear regression analysis was performed for language 
difference scores as the independent variable (along with control variables) and the 
temporal difference scores as the dependent variable. The regression analysis yielded an 
R-squared value of 0.076 and a p-value of 0.572. Neither the overall linear regression 
model nor the individual variable correlations were statistically significant. Individually, 
the language difference score variable yielded a 0.162 standardized β1 value with a p-
value of 0.293.  
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DISCUSSION 
 The multiple linear regression analyses that were run with the difference scores 
yielded results that were mostly not statistically significant. The only regression model 
that showed any statistical significance was that of the memory difference scores and the 
limbic difference scores (β1= -0.361, p=0.009). Additionally, when controlling for age of 
death, race, sex and years of education, the multiple linear regression was still statistically 
significant. The R-squared of 0.241 indicates that about 24% of the variation observed in 
the limbic NFT density of subjects can be predicted by performance in memory-related 
neuropsychological tests. By looking at the β1 value we can see that the correlation is 
negative, which indicates that for every unit of standard deviation below the mean of 
performance in memory tests (an decrease of 1 in memory difference score), there is an 
increase of 0.361 standard deviations in limbic difference scores. 
 A more simple way of interpreting these results would be to observe the 
correlation directly with neuropsychological performance and NFT densities. In a more 
simplified way, the negative correlation between memory difference scores and limbic 
difference scores indicates that the worse you perform in memory tests, the more NFTs 
are expected to be found in the limbic region. This seems logical, as it has been explained 
previously that a higher NFT density for a specific region would affect the cognitive 
domains associated with it. 
 The other four regression analyses had no statistical significance with p-values 
much larger than 0.05. Therefore, the results from our study demonstrate that the 
hypotheses presented for these regions were incorrect. Even though the strong negative 
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correlations we expected to observe were not present, there are several factors that could 
explain the lack of significant correlations, even after controlling for age of death, sex, 
race, and years of education. 
 
Study limitations and strengths 
 One of the larger study limitations was the small sample size that we used in our 
study. Since we only used subjects that were part of the BU ADC, our cohort was initially 
very limited, and having the strict inclusion criteria for the pathological sample made it 
increasingly difficult to increase our sample size. Additionally, the lack of 
neuropsychological test data for some of the subjects also forced us to exclude them from 
analysis, which further reduced our sample size.  
To simplify the statistical analyses in our study, many assumptions and 
simplifications were made with the data. One considerable simplification that was 
discussed previously was classifying the neuropsychological tests into a single cognitive 
domain. Although we classified these tests according to the cognitive domain that we 
believed they most strongly assess, the types of tests included in our study are used to 
assess performance across various cognitive domains. Simplifying the test results could 
have greatly affected the outcome of our study. 
Additionally, one of the greater assumptions made in our study was associating 
specific brain regions with only one cognitive domain. It is well known that most 
cognitive domains can be attributed to a large number of brain regions, and the 
relationships between these domains and associated regions is a lot more complex than 
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the how we have classified them in our study. Though our classifications are correct, it is 
important to acknowledge that domain and region relationships are a lot more complex 
than how we have portrayed them. 
 Another limitation for this study was the inclusion of comorbid pathologies in the 
study sample. As mentioned in the Methods section, the pathological sample included 
patients that may or may not have had comorbid pathologies along with AD pathology. 
Although it would be very difficult to find a large enough sample with purely AD 
pathology, it is understandable how having comorbid pathologies could affect the 
neuropsychological profiles of the subjects included in the study. However, having a 
large enough cohort of subjects would allow for stricter inclusion criteria that could 
address this limitation. 
Although the study had many limitations, our methodology had several strengths 
that should be implemented in future studies. One of these strengths was our NFT 
quantification methods. Up until recently, pathologists had to manually identify and 
quantify NFTs found in brain tissues, which was undoubtedly an arduous and error-prone 
process. As imaging technologies become increasingly more sophisticated, we are able to 
implement the use of elaborate algorithms to analyze tissue images, as we did in our 
study. This method eliminates inter-rater variability and provides a more accurate 
measure of NFT density. 
Additionally, when analyzing neuropsychological testing performance, most 
researchers tend to look at differences in performance across subjects within a sample. In 
this study we developed a more elegant way of performing within-subject comparisons, 
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looking at various domain deficiencies in the same subject. We achieved this by 
calculating the difference scores, which provide a measure of domain-specific 
deficiencies within a subject when compared to their global performance in 
neuropsychological testing. 
 
Future studies 
Future studies would largely benefit from a significantly larger study sample size. 
By including patients from other study cohorts that meet our inclusion criteria and 
increasing the sizes of both samples, some statistically significant correlations might 
become evident performing the same analyses we completed in our study. 
Additionally, having a more even distribution of neuropsychological tests for each 
of the domains would allow for a more complete picture of the cognitive deficits the 
subjects presented with during life. In this study, there was a larger number of memory-
related neuropsychological tests, which could explain why only memory and limbic 
difference scores showed a statistically significant correlation. 
The results of this study, although not statistically significant, will hopefully 
incentivize other researchers to delve into looking at the specific correlations that might 
be observed between atypical pathological distributions of AD and the many clinical 
presentations of atypical AD. Further understanding the presentations of atypical AD 
could eventually help properly treat and change the course of cognitive decline for 
patients suffering from these largely neglected subtypes of AD.  
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APPENDIX 
Appendix 1: The Nuclear macros algorithm parameters used for the identification 
of NFTs in the annotated slide images in the ImageScope software. 
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